$PLX Headlines In focus: Awaiting the next move 8:57

New Post Public Reply Private Reply Replies (0) Message Board

Oct 13, 2014 at 1:50 PM

$PLX Headlines

In focus: Awaiting the next move 8:57 p.m. Feb. 6, 2013 - Lawrence G. McMillan
Using Plants to Make Cheaper Biotech Drugs 10:41 a.m. July 9, 2012 - MarketWatch
Wells Fargo cuts Protalix to market perform 9:11 a.m. June 25, 2012 - Greg Morcroft
Friday’s biggest gaining and declining stocks 4:33 p.m. June 22, 2012 - MarketWatch
Wednesday’s biggest gaining and declining stocks 4:47 p.m. May 2, 2012 - MarketWatch
Protalix, Formfactor, Opentable see options volume surge 12:20 p.m. May 2, 2012 - blogs.marketwatch.com
Canaccord cuts Protalix to hold from buy 9:17 a.m. May 2, 2012 - Greg Morcroft
Genworth rises, Chesapeake falls after hours 5:24 p.m. May 1, 2012 - Myra P. Saefong
American Capital options volume surges 10:48 a.m. May 1, 2012 - blogs.marketwatch.com
Protalix prices shares at 14% discount 11:51 a.m. Feb. 16, 2012 - MarketWatch.com
Tuesday’s biggest gaining & declining stocks 5:48 p.m. Dec. 6, 2011 - Kate Gibson
Protalix shares riae 4.6% in preopen trade 8:58 a.m. Aug. 17, 2011 - Greg Morcroft
FDA accepts Protalix resubmission for Gaucher drug 8:57 a.m. Aug. 17, 2011 - MarketWatch.com
Israel stocks lower; Ness agrees to takeover 8:56 a.m. June 12, 2011 - Robert Daniel
Israel stocks fall after central bank’s rate hike 9:12 a.m. May 24, 2011 - Robert Daniel
Israel stocks edge higher, lifted by energy sector 11:12 a.m. May 19, 2011 - Robert Daniel
Israel stocks advance, led by finance, property 7:32 a.m. March 21, 2011 - Robert Daniel
Israel up as Strauss, Migdal, Gazit-Globe report 9:20 a.m. March 16, 2011 - Robert Daniel
Israel stocks lower; Prolor and Protalix ease 8:51 a.m. March 6, 2011 - Robert Daniel
Medicis, PDL lead drug stocks north 12:47 p.m. Feb. 28, 2011 - Val Brickates Kennedy

Ebola traders need to rest 10:52 a.m. Today - Seeking Alpha
Israeli Biotech Stocks Offer Low Returns For High Risk Investment 8:12 a.m. Oct. 3, 2014 - Seeking Alpha
How Protalix BioTherapeutics (PLX) Stock Stands Out in a Strong Industry - Tale of the Tape 8:42 a.m. Sept. 26, 2014 - Zacks.com
Dow 30 Stock Roundup: MSFT Widens Surface Pro 3 Availability, MCD Shutters Several Russia Units - Analyst Blog 3:12 p.m. Sept. 5, 2014 - Zacks.com
Protalix/Pfizer's Elelyso Approved in Pediatric Patients - Analyst Blog 5:00 p.m. Aug. 29, 2014 - Zacks.com
Protalix BioTherapeutics, Inc. (PLX) Jumps: Stock Adds 8.3% in Session - Tale of the Tape 9:11 a.m. Aug. 29, 2014 - Zacks.com
InsiderInsights.com Daily Round Up: 8/15/14 3:06 a.m. Aug. 17, 2014 - Seeking Alpha
Facebook Leads 3 High-Volume Young Gun Stock Leaders 6:14 p.m. June 24, 2014 - Investors Business Daily
Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog 6:15 p.m. June 19, 2014 - Zacks.com
Protalix (PLX) in Focus: Stock Adds 6.5% in Session - Tale of the Tape 9:25 a.m. June 19, 2014 - Zacks.com
Protalix commences Phase 2a Gaucher trial 9:01 a.m. June 18, 2014 - Seeking Alpha
Protalix chief to retire 9:25 a.m. June 13, 2014 - Seeking Alpha
Elelyso gets the nod in Canada 7:52 a.m. May 30, 2014 - Seeking Alpha
10-Q: PROTALIX BIOTHERAPEUTICS, INC. 4:36 p.m. May 8, 2014 - Edgar Online - (EDG = 10Q, 10K)
Relative Strength Alert For Protalix BioTherapeutics 12:22 p.m. April 25, 2014 - TheStreet.com
Protalix Biotherapeutics - A Compelling Buy Due To Validation Of Oral Protein Delivery Technology 12:33 p.m. Feb. 13, 2014 - Seeking Alpha
24/7 suggests eight biotech trading near $5 with big upside potential 9:25 a.m. Feb. 8, 2014 - Seeking Alpha
Protalix provides 2014 outlook, shares rise 10:07 a.m. Jan. 13, 2014 - Seeking Alpha
6 Biotechnology Stocks to Sell Now 6:30 a.m. Jan. 8, 2014 - InvestorPlace.com
Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More 8:47 a.m. Jan. 7, 2014 - 247WallSt.com

Protalix BioTherapeutics Appoints Moshe Manor as President and Chief Executive Officer 2:00 a.m. Sept. 29, 2014 - GlobeNewswire
Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment Conference 7:37 a.m. Sept. 4, 2014 - GlobeNewswire
Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional Programs 5:52 p.m. Aug. 28, 2014 - GlobeNewswire
Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO™ (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease 1:15 p.m. Aug. 28, 2014 - BusinessWire - BZX
Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of Directors 8:01 a.m. July 24, 2014 - GlobeNewswire
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting 7:01 a.m. June 27, 2014 - GlobeNewswire
Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher Disease 7:31 a.m. June 18, 2014 - GlobeNewswire
Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This Year 8:01 a.m. June 13, 2014 - GlobeNewswire
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients 7:31 a.m. May 30, 2014 - GlobeNewswire
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences 7:32 a.m. May 28, 2014 - GlobeNewswire
Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric Patients 7:32 a.m. May 22, 2014 - GlobeNewswire
Protalix BioTherapeutics to Present at the Oppenheimer 15th Annual Israeli Conference and the MIXiii Israel Innovation Conference, Biomed 7:31 a.m. May 7, 2014 - GlobeNewswire
Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 Meeting 8:32 a.m. April 23, 2014 - GlobeNewswire
Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014 8:30 a.m. Feb. 12, 2014 - GlobeNewswire
Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial Property 8:30 a.m. Feb. 6, 2014 - GlobeNewswire
Protalix Announces Successful Manufacturing Facility Evaluation by Health Canada 5:30 p.m. Jan. 23, 2014 - GlobeNewswire
Protalix BioTherapeutics Provides Full-Year 2014 Strategic Outlook 8:30 a.m. Jan. 13, 2014 - GlobeNewswire
Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:30 a.m. Jan. 7, 2014 - GlobeNewswire
Protalix BioTherapeutics to Present at Oppenheimer's 24th Annual Healthcare Conference 10:00 a.m. Dec. 3, 2013 - GlobeNewswire
Protalix BioTherapeutics to Present at Upcoming Scientific and Medical Meetings 10:10 a.m. Oct. 31, 2013 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shell Seals ARC Acquisition, $16.5B Bet on Future

Shell’s Strategic Play: Snagging ARC When it comes to Shell, they don't dawdle with peanuts. Snagging ARC Resources Ltd., a Canadian energy firm rooted squarely in British Columbia and Alberta, speaks volumes about their appetite for growth. They’re shelling out approximately US$16.5 billion to pull this deal off the ground. This isn't just some casual sector play; it...

HIMS Faces Class Action: Investors Eye Leadership

Another Day, Another Lawsuit: Hims & Hers in Hot Water Here's the latest conundrum in the corporate world, folks. Hims & Hers Health, Inc. (NYSE: HIMS) is caught up in a class action lawsuit that could shake up the telehealth scene. Investors who found themselves knee-deep in losses during the class period from August 2025 to July 2026 might want to pay attention. The...

VT Markets Appoints Maxwell for Global Expansion

Maxwell Joins VT Markets Amid Strategic Shift Forget the usual humdrum of C-suite comings and goings; this one's packed with punch. VT Markets is setting the stage for a serious leap forward by naming Ross Maxwell their new Chief Strategy Officer. This isn't just another desk job—it's a pivotal role meant to integrate cutting-edge technology with the ever-evolving...

RealityMine Appoints CPO Amidst Strong Growth Momentum

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Capricor Faces Lawsuit: Investors Should Take Note

Capricor Therapeutics: A Rough Road Ahead If you've got skin in the game with Capricor Therapeutics, these latest developments might have you feeling a bit queasy. Forget the greasy diner fare today; this situation calls for some serious contemplation and maybe a bit of antacid. Over at NASDAQ:CAPR, the air is hot with allegations, stock price nosedives, and looming legal...

Joseph Spine Opens New Regenerative Therapy Center

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Check Point Shareholders Back 2026 AGM Proposals

Shareholder Endorsement Solidifies Check Point's Strategy Today, Check Point Software Technologies had a bit of a celebratory mood. Their stakeholders, it seems, aren't just riding the wave; they're all in. You could almost hear the cheers from Redwood City when those shareholder voting results flashed across the board. Some 81.2 million shares—encompassing about 79.52%...

TCOM Secures $600M Deal to Boost NATO's Defense

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

ITP Media's Bold Move: Ready for Asian Market Surge

Pushing Boundaries: ITP Media Group Eyes Asia ITP Media Group isn't here to tiptoe around the media market; they're diving headfirst with the recent takeover of Heart Media Group. A bold move, some might say, in this volatile world of media mergers and acquisitions. But let's break down what this really means. A Strategic Bet on Luxury To start, ITP Media is beefing up...

Ecobat's Strategic Shift: Exiting Lithium for Lead

You ever get that sense of déjà vu when another company decides to jump ship from a supposedly hot market? Well, that's where Ecobat's at, folks. This global player in battery recycling just waved goodbye to its lithium recycling biz, closing the deal on its Arizona operations. Previously, they ditched similar holdings in the UK and Germany. Now, they're all-in on their...